Tumor-specific expression of HMG-CoA reductase in a population-based cohort of breast cancer patients.

Research output: Contribution to journalArticle

Abstract

The mevalonate pathway synthetizes cholesterol, steroid hormones, and non-steriod isoprenoids necessary for cell survival. 3-Hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR) is the rate-limiting enzyme of the mevalonate pathway and the target for statin treatment. HMGCR expression in breast tumors has recently been proposed to hold prognostic and treatment-predictive information. This study aimed to investigate whether HMGCR expression in breast cancer patients was associated with patient and tumor characteristics and disease-free survival (DFS).

Details

Authors
Organisations
Research areas and keywords

Subject classification (UKÄ) – MANDATORY

  • Cancer and Oncology
Original languageEnglish
Article number8
JournalBMC Clinical Pathology
Volume15
Publication statusPublished - 2015
Publication categoryResearch
Peer-reviewedYes

Total downloads

No data available